1. Home
  2. SKYH vs HELP Comparison

SKYH vs HELP Comparison

Compare SKYH & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sky Harbour Group Corporation

SKYH

Sky Harbour Group Corporation

HOLD

Current Price

$8.88

Market Cap

324.6M

Sector

Industrials

ML Signal

HOLD

HELP

Cybin Inc. Common Stock

N/A

Current Price

$6.81

Market Cap

303.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SKYH
HELP
Founded
2017
N/A
Country
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
324.6M
303.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SKYH
HELP
Price
$8.88
$6.81
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$13.83
N/A
AVG Volume (30 Days)
130.1K
504.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$95.36
N/A
Revenue Next Year
$69.38
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.22
$4.81
52 Week High
$14.20
$10.07

Technical Indicators

Market Signals
Indicator
SKYH
HELP
Relative Strength Index (RSI) 45.50 51.00
Support Level $8.28 $5.88
Resistance Level $9.42 $6.65
Average True Range (ATR) 0.38 0.59
MACD -0.05 -0.01
Stochastic Oscillator 46.40 70.13

Price Performance

Historical Comparison
SKYH
HELP

About SKYH Sky Harbour Group Corporation

Sky Harbour Group Corp is an aviation infrastructure company building a nationwide network of Home-based solutions for business aircraft. The company develops, leases, and manages business aviation hangars across the United States based on its proprietary targeting and acquisition model, targeting airfields with hangar supply and demand imbalances in the markets. Its hangar campuses feature exclusive private hangars and a full suite of dedicated services specifically designed for home-based aircraft.

About HELP Cybin Inc. Common Stock

Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.

Share on Social Networks: